Zacks Investment Research upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a sell rating to a hold rating in a report released on Thursday morning, Zacks.com reports.

According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “

EXAS has been the topic of a number of other research reports. Canaccord Genuity increased their price target on Ideagen from GBX 170 ($2.22) to GBX 180 ($2.35) and gave the company a buy rating in a research note on Wednesday, July 17th. Jefferies Financial Group increased their price target on EXACT Sciences from $100.00 to $115.00 and gave the company a buy rating in a research note on Wednesday, May 1st. Craig Hallum upped their price objective on shares of 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a buy rating in a research report on Wednesday, May 1st. BidaskClub cut shares of Ames National from a hold rating to a sell rating in a research report on Wednesday, July 17th. Finally, BTIG Research upped their price objective on shares of Apple to $234.00 and gave the company a buy rating in a research report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $109.82.

NASDAQ:EXAS opened at $117.92 on Thursday. The stock’s fifty day moving average price is $114.96. EXACT Sciences has a 52-week low of $47.78 and a 52-week high of $121.98. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. The firm has a market cap of $15.23 billion, a P/E ratio of -86.71 and a beta of 1.64.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.01). The firm had revenue of $162.00 million for the quarter, compared to analyst estimates of $153.07 million. EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The firm’s quarterly revenue was up 79.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.33) EPS. Analysts forecast that EXACT Sciences will post -2.2 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. UBP Investment Advisors SA acquired a new position in shares of EXACT Sciences during the 1st quarter worth about $286,000. Great Valley Advisor Group Inc. boosted its stake in shares of EXACT Sciences by 85.3% during the 1st quarter. Great Valley Advisor Group Inc. now owns 9,129 shares of the medical research company’s stock worth $791,000 after buying an additional 4,203 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of EXACT Sciences during the 1st quarter worth about $495,000. GAM Holding AG acquired a new position in shares of EXACT Sciences during the 1st quarter worth about $2,745,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of EXACT Sciences during the 1st quarter worth about $618,000. Hedge funds and other institutional investors own 86.72% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Article: Total Return

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.